Understanding how SIRT1 affects RNA stability in breast cancer
SIRT1 Regulates RNA Stability to Promote Breast Cancer
['FUNDING_OTHER'] · DANA-FARBER CANCER INST · NIH-11094157
This study is looking at how a protein called SIRT1 affects the growth of aggressive breast cancer and how lower levels of this protein can lead to the spread of cancer cells, with the hope of finding new ways to treat the disease.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11094157 on ClinicalTrials.gov |
What this research studies
This research investigates the role of SIRT1, a protein that regulates RNA stability, in the progression of aggressive breast cancer. The study focuses on how decreased levels of SIRT1 lead to increased production of exosomes, which are small vesicles that can promote cancer cell survival and spread. By examining the molecular mechanisms involved, particularly the interaction between SIRT1 and RNA binding proteins, the researchers aim to uncover new strategies for treating breast cancer. Patients may benefit from insights that could lead to novel therapeutic approaches targeting these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with aggressive forms of breast cancer, particularly those experiencing advanced disease progression.
Not a fit: Patients with non-aggressive breast cancer or those not diagnosed with breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for patients with aggressive breast cancer.
How similar studies have performed: Other research has shown promising results in targeting RNA stability and exosome production in cancer, indicating that this approach may hold potential for significant advancements.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, FANGYU — DANA-FARBER CANCER INST
- Study coordinator: WANG, FANGYU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: aggressive breast cancer, Breast Cancer, Breast Cancer Cell, breast cancer progression, Cancer Biology